1. Home
  2. FLR vs PCVX Comparison

FLR vs PCVX Comparison

Compare FLR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluor Corporation

FLR

Fluor Corporation

SELL

Current Price

$48.40

Market Cap

7.0B

Sector

Industrials

ML Signal

SELL

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

SELL

Current Price

$61.62

Market Cap

7.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FLR
PCVX
Founded
1912
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
7.0B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
FLR
PCVX
Price
$48.40
$61.62
Analyst Decision
Buy
Strong Buy
Analyst Count
9
11
Target Price
$59.56
★ $116.40
AVG Volume (30 Days)
★ 2.3M
1.8M
Earning Date
11-06-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 3.04
N/A
Revenue
★ $15,503,000,000.00
N/A
Revenue This Year
$2.81
N/A
Revenue Next Year
$11.01
N/A
P/E Ratio
$16.15
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$39.33
$42.40
52 Week High
$58.35
$90.75

Technical Indicators

Market Signals
Indicator
FLR
PCVX
Relative Strength Index (RSI) 49.36 47.18
Support Level $47.21 $58.85
Resistance Level $49.85 $62.44
Average True Range (ATR) 2.06 2.97
MACD 0.44 -0.03
Stochastic Oscillator 61.18 26.56

Price Performance

Historical Comparison
FLR
PCVX

About FLR Fluor Corporation

Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: